Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martim Luz

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The Journal of Dermatological Treatment|February 11, 2025
Oral roflumilast for psoriasis: a real-world 24-week prospective cohort studyAna Maria Lé, Orhan Yilmaz, Martim Luz, et al.
The Journal of Dermatological Treatment|May 6, 2026
Complete clearance of high-impact sites with risankizumab in patients with psoriasis: a 2-year real-world retrospective multicenter cohort studyMargarida Contente, Ana Luísa João, Martim Luz, et al.
BMJ Open|May 19, 2026
Global Healthcare Study on Psoriasis (GHSP): cohort profile and first findingsJulia-Tatjana Maul, Fabienne Fröhlich, Mia-Louise Nielsen, et al.
The Journal of Dermatological Treatment|January 23, 2026
Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohortDiego Orsini, Luca Potestio, Matteo Megna, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The Journal of Dermatological Treatment|February 11, 2025
Oral roflumilast for psoriasis: a real-world 24-week prospective cohort studyAna Maria Lé, Orhan Yilmaz, Martim Luz, et al.
The Journal of Dermatological Treatment|May 6, 2026
Complete clearance of high-impact sites with risankizumab in patients with psoriasis: a 2-year real-world retrospective multicenter cohort studyMargarida Contente, Ana Luísa João, Martim Luz, et al.
BMJ Open|May 19, 2026
Global Healthcare Study on Psoriasis (GHSP): cohort profile and first findingsJulia-Tatjana Maul, Fabienne Fröhlich, Mia-Louise Nielsen, et al.
The Journal of Dermatological Treatment|January 23, 2026
Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohortDiego Orsini, Luca Potestio, Matteo Megna, et al.
Pageof 1